<DOC>
	<DOCNO>NCT00763750</DOCNO>
	<brief_summary>The purpose study determine antitumor activity PPX combination temozolomide radiation patient newly diagnose brain tumor .</brief_summary>
	<brief_title>BrUOG-Brain-223 : A Study PPX ( CT-2103 ) , Temozolomide , Concurrent Radiation Newly Diagnosed Brain Tumors ( CTI # CT2103 )</brief_title>
	<detailed_description>To evaluate safety/tolerability potential antitumor activity PPX combination temozolomide radiation patient newly diagnose brain tumor .</detailed_description>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<criteria>Patients must histopathologically confirm , newly diagnose , glioblastoma multiforme anaplastic glioma ( anaplastic astrocytoma [ AA ] , anaplastic oligodendroglioma , anaplastic oligoastrocytoma ) complete surgical resection . Patients must 18 year age old . Patients must Zubrod performance status 02 . Patients must enzymeinducing antiepileptic drug ( EIAED ) . Patients may nonenzyme induce antiepileptic drug ( NEIAED ) may take antiepileptic drug . Patients must receive prior chemotherapy , radiation experimental therapy glioblastoma . Patients may breastfeed child . Female patient must either child bear potential negative pregnancy test within 14 day start study treatment . Patients consider child bear potential surgically sterile ( undergone hysterectomy , bilateral tubal ligation , bilateral oophorectomy ) postmenopausal . Pregnant lactating female eligible . Should woman become pregnant suspect pregnant participating study , inform treat physician immediately . Female patient must use acceptable method contraception ( oral contraceptive , barrier method , approve contraceptive implant , longterm injectable contraception , intrauterine device tubal ligation ) OR female patient must least 1year postmenopausal surgically sterile participation study ( time sign consent form ) prevent pregnancy . Male patient must surgically sterile use acceptable method contraception participation study ( time sign consent form ) prevent pregnancy partner Patients must concurrent malignancy except curatively treat basal squamous cell carcinoma skin carcinoma situ cervix breast . Patients prior malignancy must diseasefree â‰¥ 2 year . Patients must normal organ marrow function define : Absolute neutrophil count &gt; 1,500/ul Platelets &gt; 100,000/ul Hemoglobin &gt; 8 gm/dL Total bilirubin &lt; 1.5 x ULN Creatinine &lt; 1.5 x ULN Patient must capacity understand willingness sign write informed consent document . Patient must able tolerate MRIs . CT scan NOT substitute MRI study . Recurrent malignant glioma . Tumor focus detect tentorium beyond cranial vault . Allergy gadolinium contraindication MRI scan . Patients receive form brachytherapy radiosurgery glioblastoma prior start standard radiation . History allergic reaction attribute compound similar chemical biologic composition PPX . Uncontrolled intercurrent illness include , limited , hypertension ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . Pregnant woman exclude study . Because unknown potential risk adverse event nurse infant secondary treatment mother PPX , breastfeed discontinue mother treated PPX .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>glioblastoma multiforme anaplastic glioma</keyword>
</DOC>